STOCK TITAN

Wellington Management Group (CRNX) reports 7.79% beneficial stake in Crinetics

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Wellington Management Group LLP amended its Schedule 13G/A to report 7.79% beneficial ownership of Crinetics Pharmaceuticals, Inc. common stock. The filing lists shared voting power and shared dispositive power across related Wellington entities, including 8,157,204 shares of shared dispositive power as reported on cover pages.

Positive

  • None.

Negative

  • None.

Insights

Wellington reports a roughly 7.8% passive stake across affiliated entities.

The filing shows aggregated 7.79% beneficial ownership with shared voting and dispositive power reported across multiple Wellington entities. This is consistent with passive, advisory-held positions disclosed on a Schedule 13G/A rather than an active Schedule 13D.

Future filings may show changes if client mandates or dispositions occur; timing not specified in the excerpt.

Multiple Wellington entities are listed with shared control metrics and parent/subsidiary structure.

The filing details the internal structure: parent holding companies and identified investment advisers that hold the securities of record for clients, and lists entities with shared voting power (e.g., 7,143,677) and shared dispositive power (e.g., 8,157,204).

These allocations reflect recordkeeping and advisory relationships; any material change would appear in subsequent amendments.

Beneficial ownership 7.79% Schedule 13G/A amendment reporting
Shared dispositive power 8,157,204 shares Cover page aggregated shared dispositive power
Shared voting power (example) 7,143,677 shares Listed for several Wellington entities on cover pages
Schedule 13G/A regulatory
"Amendment No. 4 and Schedule 13G/A cover pages showing beneficial ownership"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficial ownership regulatory
"Item 4(a) Amount beneficially owned: See the responses to Item 9"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared dispositive power regulatory
"Shared Dispositive Power 8,157,204.00 listed on cover pages"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Wellington Management report in CRNX?

Wellington reports 7.79% beneficial ownership of Crinetics Pharmaceuticals common stock. The filing presents shared voting and dispositive power across affiliated Wellington entities and lists 8,157,204 shares of shared dispositive power on the cover pages.

Which Wellington entities are named on the Schedule 13G/A for CRNX?

The filing names Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP. It also references related investment advisers that hold securities of record for clients of the Wellington group.

Does the filing indicate sole voting or dispositive power over CRNX shares?

No sole power is reported; the cover responses show 0 shares of sole voting and sole dispositive power. The filing reports shared voting power and shared dispositive power across Wellington entities instead.

Is this Schedule 13G/A an active or passive disclosure for CRNX?

This is a Schedule 13G/A disclosure indicating beneficial ownership by investment-adviser-related entities, consistent with a passive/Section 13(g) reporting profile rather than an active Schedule 13D seeking control.





22663K107

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:05/15/2026
Wellington Group Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:05/15/2026
Wellington Investment Advisors Holdings LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:05/15/2026
Wellington Management Company LLP
Signature:Matthew Revell
Name/Title:Compliance Manager
Date:05/15/2026